Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Cybin (CYBN) announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

PharmacoEconomics: “Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.” GoodTherapy ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .